Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

ZG-2291

Copy Product Info
😃Good
Catalog No. T89209Cas No. 2962103-40-6

ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.

ZG-2291

ZG-2291

Copy Product Info
😃Good
Catalog No. T89209Cas No. 2962103-40-6
ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
25 mg$1,5207-10 days7-10 days
50 mg$1,9807-10 days7-10 days
100 mg$2,5007-10 days7-10 days
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.
In vitro
ZG-2291 (5 or 20 μM, 48 hours) acts as an active cell-penetrating FIH inhibitor in Hep3B cells. Additionally, ZG-2291 enhances thermogenesis and improves lipid accumulation in 3T3-L1 derived adipocytes.
In vivo
Administered every other day for 30 days at a dosage of 10 mg/kg via intraperitoneal injection, ZG-2291 effectively combats obesity symptoms in ob/ob mice and significantly ameliorates associated metabolic dysfunctions.
Chemical Properties
Molecular Weight373.75
FormulaC17H12ClN3O5
Cas No.2962103-40-6
SmilesO=C(O)CNC(=O)C=1N=CC(=CC1O)C=2ON=C(C2)C=3C=CC=C(Cl)C3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy ZG-2291 | purchase ZG-2291 | ZG-2291 cost | order ZG-2291 | ZG-2291 chemical structure | ZG-2291 in vivo | ZG-2291 in vitro | ZG-2291 formula | ZG-2291 molecular weight